Cart
sales@molnova.com
KY-05009
CAS No. 1228280-29-2
KY-05009( —— )
Catalog No. M26273 CAS No. 1228280-29-2
KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 45 | In Stock |
|
| 5MG | 41 | In Stock |
|
| 10MG | 62 | In Stock |
|
| 25MG | 113 | In Stock |
|
| 50MG | 161 | In Stock |
|
| 100MG | 239 | In Stock |
|
| 200MG | 347 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKY-05009
-
NoteResearch use only, not for human use.
-
Brief DescriptionKY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells.
-
DescriptionKY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity. KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor (Ki = 100 nM). (In Vitro):KY-05009 (1-3 μM; 48-72 hours; RPMI8226 cells) treatment induces caspase-dependent apoptosis in RPMI8226 cells in a dose-dependent manner. KY-05009 (3 μM; 1 hour; RPMI8226 cells) treatment suppresses the transcriptional activity of Wnt signaling-related genes, including TNIK, CTNNB1, TCF7, and TCF4. KY-05009 (3 μM; 9 hours; RPMI8226 cells) treatment inhibits the IL-6-induced interaction between TCF4 and β-catenin and the phosphorylation of TCF4.KY-05009 (0.1-30 μM; 24 hours; RPMI8226 cells) treatment inhibits the proliferation of RPMI8226 cells in a dose-dependent manner.
-
In VitroCell Proliferation Assay Cell Line:RPMI8226 cells Concentration:0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM, 30 μM Incubation Time:24 hours Result:Inhibited the proliferation of RPMI8226 cells.Apoptosis Analysis Cell Line:RPMI8226 cells Concentration:1 μM, 3 μM, 10 μM Incubation Time:48 hours, 72 hours Result:Induced the binding of fluorescent Annexin V and 7-amino-actinomycin D (7-AAD) uptake.RT-PCR Cell Line:RPMI8226 cells Concentration:3 μM Incubation Time:1 hour Result:Suppressed the transcriptional activity of Wnt signaling-related genes, including TNIK, CTNNB1, TCF7, and TCF4.Western Blot Analysis Cell Line:RPMI8226 cells Concentration:3 μM Incubation Time:9 hours Result:The IL-6-induced interaction between TCF4 and β-catenin and the phosphorylation of TCF4 were inhibited.
-
In Vivo——
-
Synonyms——
-
PathwayWnt/Notch/Hedgehog
-
TargetWnt/beta/catenin
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1228280-29-2
-
Formula Weight352.41
-
Molecular FormulaC18H16N4O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (236.46 mM)
-
SMILESCc1ccc(cc1)C(=O)Nc1sc(Nc2ccccc2)nc1C(N)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Groome NP. Superiority of ABTS over Trinder reagent as chromogen in highly sensitive peroxidase assays for enzyme linked immunoadsorbent assay. J Clin Chem Clin Biochem. 1980 Jun;18(6):345-9.
molnova catalog
related products
-
WIC1
WIC1 is a potent Wnt inhibitor. WIC1 can be used in cancer research
-
Wnt pathway activato...
Wnt pathway activator 1 is a potent Wnt activator with an IC50 of 28-29 nM. Wnt pathway activator 1 is a potent Wnt activator for the treatment of androgenetic alopecia (AGA) extracted from patent WO2012024404A1.
-
TNKS-2-IN-1
TNKS-2-IN-1 is a TNKS-2 inhibitor.TNKS-2-IN-1 inhibits TNKS-1 and TNKS-2 with IC50s of 259 nM and 1100 nM, respectively.TNKS-2-IN-1 has antimicrobial activity against E. coli and S. aureus.
